Grifols is working with various government health authorities, plasma donation centers, research institutes, universities and hospitals across the world on several international clinical trials.

Potential Therapy with
Anti-SARS-CoV-2 Hyperimmune Globulin

Grifols started the production of a new anti-SARS-CoV-2 hyperimmune globulin, during the second week of June in its facility in Clayton, North Carolina.

Hyperimmune globulins are designed to give a patient passive immunity against a specific disease. They contain high concentration of antibodies, and can offer precise and consistent dosing with high purity, high potency and a strong safety profile, which  may help a patient's immune system respond to infections.

Our existing knowledge collecting plasma in epidemic settings, which was the case in the most recent Ebola outbreak in Liberia, our extensive network of donor centers and availability of a purpose-built facility in Clayton, North Carolina, with already trained staff to develop medicines for infectious diseases, has enabled us to accelerate the production of this anti-SARS-CoV-2 hyperimmune globulin.

Ready to move decisively against COVID-19

Grifols has over 100 years of extensive experience in the research, development and successful application of plasma-derived therapies, including hyperimmune globulins for the prevention and treatment of well-known diseases such as tetanus, rabies or hepatitis B.

Clinical trials with Grifols' anti-SARS-CoV-2 hyperimmune globulin are being developed through a formal collaboration with the United States Food and Drug Administration (FDA), Biomedical Advanced Research Development Authority (BARDA) and the National Institutes of Health (NIH).

Anti-SARS-CoV-2 Hyperimmune Globulin

Plasma from recovered COVID-19 donors can be converted into a potential treatment, containing high and consistent concentrations of antibodies.

Potential Therapy with Convalescent Plasma for Direct Transfusion

In addition to the hyperimmune globulin, Grifols is currently conducting several clinical trials in collaboration with health regulatory agencies, both in Europe and the U.S., selected blood banks, transfusion centers and public hospitals. The aim of these trials is to study the safety and efficacy of plasma from recovered COVID-19 donors that has been virally inactivated with methylene blue.

Methylene blue inactivation

Direct transfusion of convalescent plasma to COVID-19 patients might help treat the disease. Before transfusion, the convalescent plasma is pathogen-inactivated with methylene blue technology to ensure safety.

Potential Therapies with Other Existing Plasma-derived Medicines 

Grifols is currently collaborating with a range of different experts, academics, hospitals and researchers across both the U.S. and Europe to evaluate the efficacy of other existing
plasma-derived medicines for the treatment of patients with COVID-19.

These products range from existing intravenous immunoglobulin to alpha-1 antitrypsin.

Everything starts with donations

If you have recovered from COVID-19 and would like to donate plasma and help fight the pandemic, please consider giving your plasma at a donation center or blood bank near you.

Now more than ever, we are extremely grateful to those who donate.

Donate in US

If you want to be a donor and you live in US go to Grifols Plasma

Donate in Germany

If you want to be a donor and you live in Germany go to Haema

Donate in Spain

If you want to be a donor and you live in Spain go to BTS

Grifols is proud to be part of a coalition of world-class medical and research institutions, blood centers, life science companies, philanthropic organizations and COVID-19 survivor groups that has come together to mobilize tens of thousands of people in the United States who have recovered from COVID-19 to donate their plasma, which contains essential antibodies that have fought off the disease and could help others do the same.



Go to


From donors to patients

What makes Grifols unique is that people, from donors to patients, are at the heart of everything we do.

Read more

What is plasma?

Human plasma is the liquid part of blood. It contains critical proteins responsible for important life functions.

Read more

What is plasmapheresis?

A specialized procedure to collect plasma in which machines separate plasma from whole blood and return the  blood cells  to the donor.

Read more